Document is current
Any future updates will be listed below
-
Authors
Yepes-Cortés, Carlos A. https://orcid.org/0000-0001-8588-5589
Cardenas-Moreno, Isabel C. https://orcid.org/0000-0002-8663-173X
Daza-Arnedo, Rodrigo https://orcid.org/0000-0002-6295-4972
Feriz-Bonelo, Karen M. https://orcid.org/0000-0003-1207-4245
Yama-Mosquera, Erica https://orcid.org/0000-0002-9247-4953
Ramirez-Rincón, Alex H. https://orcid.org/0000-0002-3925-6201
Castillo-Barrios, Gilberto A.
Suarez-Rodriguez, Andres F. https://orcid.org/0009-0004-6502-0819
Carreño-Jiménez, Johanna https://orcid.org/0009-0001-4600-1389
Builes-Montaño, Carlos E. https://orcid.org/0000-0002-2418-6159
-
Funding
Funding for this research was provided by:
No Nordisk Colombia
- License Information
-
More Information
Article History
Received: 23 January 2025
Accepted: 28 February 2025
First Online: 24 March 2025
Declarations
:
: The authors declare the following conflicts of interest: Carlos E. Builes-Montaño has received consulting or speaker fees from Sanofi, Novo Nordisk, Novartis, and Boehringer Ingelheim. Carlos A. Yepes-Cortés has recived consulting or speaker fees form Sanofi, Novo Nordisk, Medtronic, Bayer and Abbott. Isabel C. Cardenas-Moreno has received consulting or speaker fees from Astrazeneca, Novo Nordisk, Novartis, Sanofi and Boehringer Ingelheim. Erica Yama-Mosquera has received consulting or speaker fee from Astrazeneca, Novo Nordisk, Sanofi, Boheringer Ingelh. Carlos E. Builes-Montaño is the CEO of Festina Lente. Carlos A. Yepes-Cortés, Isabel C. Cardenas-Moreno, Rodrigo Daza-Arnedo, Karen M. Feriz-Bonelo, Erica Yama-Mosquera, Alex H. Ramirez-Rincón and Gilberto A. Castillo-Barrios, were reimbursed by Novo Nordisk Colombia for participating in the Nominal Group meeting. Andres F. Suarez-Rodriguez and Johanna Carreño-Jiménez are Novo Nordisk employees.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
